Cargando…

Analysis of the Breast Cancer Journey in Namibia

IMPORTANCE: Breast cancer (BC) is the leading cancer among women in Namibia. Examining the BC journey in this multiracial country where inequalities remain large is needed to inform effective interventions to reduce BC mortality. OBJECTIVE: To describe the entire BC journey of Namibian women by race...

Descripción completa

Detalles Bibliográficos
Autores principales: Boucheron, Pauline, Zietsman, Annelle, Pontac, Johanna, Hansen, Rolf, Anderson, Benjamin O., Togawa, Kayo, Macharia, Peter M., Foerster, Milena, Schüz, Joachim, dos-Santos-Silva, Isabel, McCormack, Valerie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625043/
https://www.ncbi.nlm.nih.gov/pubmed/37921764
http://dx.doi.org/10.1001/jamanetworkopen.2023.41402
_version_ 1785131043880173568
author Boucheron, Pauline
Zietsman, Annelle
Pontac, Johanna
Hansen, Rolf
Anderson, Benjamin O.
Togawa, Kayo
Macharia, Peter M.
Foerster, Milena
Schüz, Joachim
dos-Santos-Silva, Isabel
McCormack, Valerie
author_facet Boucheron, Pauline
Zietsman, Annelle
Pontac, Johanna
Hansen, Rolf
Anderson, Benjamin O.
Togawa, Kayo
Macharia, Peter M.
Foerster, Milena
Schüz, Joachim
dos-Santos-Silva, Isabel
McCormack, Valerie
author_sort Boucheron, Pauline
collection PubMed
description IMPORTANCE: Breast cancer (BC) is the leading cancer among women in Namibia. Examining the BC journey in this multiracial country where inequalities remain large is needed to inform effective interventions to reduce BC mortality. OBJECTIVE: To describe the entire BC journey of Namibian women by race, utilizing the World Health Organization Global Breast Cancer Initiative (GBCI) framework. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used the Namibian subset of the African Breast Cancer–Disparities in Outcomes prospective cohort. Participants were all Namibian residents with confirmed incident BC who presented at the main national public oncology center of the Windhoek Central Hospital (WCH). Follow-up started from recruitment (September 8, 2014, to October 5, 2016) and ended up to 3 years after diagnosis (December 13, 2014, to September 27, 2019). Data analysis was conducted from June 2022 to August 2023. EXPOSURES: Participants’ self-reported ethnicities were aggregated into 3 population groups: Black, mixed ancestry, and White. MAIN OUTCOMES AND MEASURES: Three-year overall survival (OS) was examined using Cox models, and summary statistics were used to describe women’s BC journey, including GBCI pillar key performance indicators: (1) early stage (TNM I or II) diagnosis (population benchmark ≥60%), (2) prompt diagnosis, ie, 60 days or less to first health care practitioner visit (population benchmark 100%), and (3) completion of recommended multimodal treatment (MT, ie, surgery plus chemotherapy) (population benchmark ≥80%). RESULTS: Of 405 women, there were 300 (74%) Black (mean [SD] age, 53 [15] years), 49 (12%) mixed ancestry (mean [SD] age, 53 [7] years), and 56 (14%) White (mean [SD] age, 59 [12] years) patients. Three-year OS was lowest in Black women (60% [95% CI, 54%-66%]; mixed ancestry: 80% [95% CI, 65%-89%]; White: 89% [95% CI, 77%-95%]), who had lower prevalence of early stage diagnosis (Black: 37% [95% CI, 31%-42%]; mixed ancestry and White: 75% [95% CI, 66%-83%]) and timely diagnosis (Black: 60% [95% CI, 54%-66%]; mixed ancestry and White: 77% [95% CI, 69%-85%]), while MT completion (Black: 53% [95% CI, 46%-59%]; mixed ancestry and White: 63% [95% CI, 50%-73%]) was low in all women. CONCLUSIONS AND RELEVANCE: In this cohort study of 405 Namibian residents with BC, marked racial disparities in survival were paralleled by inequities all along the BC journey. To improve BC survival, interventions are needed to promote earlier diagnosis in Black Namibian women and to increase MT initiation and completion in all women.
format Online
Article
Text
id pubmed-10625043
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-106250432023-11-05 Analysis of the Breast Cancer Journey in Namibia Boucheron, Pauline Zietsman, Annelle Pontac, Johanna Hansen, Rolf Anderson, Benjamin O. Togawa, Kayo Macharia, Peter M. Foerster, Milena Schüz, Joachim dos-Santos-Silva, Isabel McCormack, Valerie JAMA Netw Open Original Investigation IMPORTANCE: Breast cancer (BC) is the leading cancer among women in Namibia. Examining the BC journey in this multiracial country where inequalities remain large is needed to inform effective interventions to reduce BC mortality. OBJECTIVE: To describe the entire BC journey of Namibian women by race, utilizing the World Health Organization Global Breast Cancer Initiative (GBCI) framework. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used the Namibian subset of the African Breast Cancer–Disparities in Outcomes prospective cohort. Participants were all Namibian residents with confirmed incident BC who presented at the main national public oncology center of the Windhoek Central Hospital (WCH). Follow-up started from recruitment (September 8, 2014, to October 5, 2016) and ended up to 3 years after diagnosis (December 13, 2014, to September 27, 2019). Data analysis was conducted from June 2022 to August 2023. EXPOSURES: Participants’ self-reported ethnicities were aggregated into 3 population groups: Black, mixed ancestry, and White. MAIN OUTCOMES AND MEASURES: Three-year overall survival (OS) was examined using Cox models, and summary statistics were used to describe women’s BC journey, including GBCI pillar key performance indicators: (1) early stage (TNM I or II) diagnosis (population benchmark ≥60%), (2) prompt diagnosis, ie, 60 days or less to first health care practitioner visit (population benchmark 100%), and (3) completion of recommended multimodal treatment (MT, ie, surgery plus chemotherapy) (population benchmark ≥80%). RESULTS: Of 405 women, there were 300 (74%) Black (mean [SD] age, 53 [15] years), 49 (12%) mixed ancestry (mean [SD] age, 53 [7] years), and 56 (14%) White (mean [SD] age, 59 [12] years) patients. Three-year OS was lowest in Black women (60% [95% CI, 54%-66%]; mixed ancestry: 80% [95% CI, 65%-89%]; White: 89% [95% CI, 77%-95%]), who had lower prevalence of early stage diagnosis (Black: 37% [95% CI, 31%-42%]; mixed ancestry and White: 75% [95% CI, 66%-83%]) and timely diagnosis (Black: 60% [95% CI, 54%-66%]; mixed ancestry and White: 77% [95% CI, 69%-85%]), while MT completion (Black: 53% [95% CI, 46%-59%]; mixed ancestry and White: 63% [95% CI, 50%-73%]) was low in all women. CONCLUSIONS AND RELEVANCE: In this cohort study of 405 Namibian residents with BC, marked racial disparities in survival were paralleled by inequities all along the BC journey. To improve BC survival, interventions are needed to promote earlier diagnosis in Black Namibian women and to increase MT initiation and completion in all women. American Medical Association 2023-11-03 /pmc/articles/PMC10625043/ /pubmed/37921764 http://dx.doi.org/10.1001/jamanetworkopen.2023.41402 Text en Copyright 2023 Boucheron P et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Boucheron, Pauline
Zietsman, Annelle
Pontac, Johanna
Hansen, Rolf
Anderson, Benjamin O.
Togawa, Kayo
Macharia, Peter M.
Foerster, Milena
Schüz, Joachim
dos-Santos-Silva, Isabel
McCormack, Valerie
Analysis of the Breast Cancer Journey in Namibia
title Analysis of the Breast Cancer Journey in Namibia
title_full Analysis of the Breast Cancer Journey in Namibia
title_fullStr Analysis of the Breast Cancer Journey in Namibia
title_full_unstemmed Analysis of the Breast Cancer Journey in Namibia
title_short Analysis of the Breast Cancer Journey in Namibia
title_sort analysis of the breast cancer journey in namibia
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625043/
https://www.ncbi.nlm.nih.gov/pubmed/37921764
http://dx.doi.org/10.1001/jamanetworkopen.2023.41402
work_keys_str_mv AT boucheronpauline analysisofthebreastcancerjourneyinnamibia
AT zietsmanannelle analysisofthebreastcancerjourneyinnamibia
AT pontacjohanna analysisofthebreastcancerjourneyinnamibia
AT hansenrolf analysisofthebreastcancerjourneyinnamibia
AT andersonbenjamino analysisofthebreastcancerjourneyinnamibia
AT togawakayo analysisofthebreastcancerjourneyinnamibia
AT machariapeterm analysisofthebreastcancerjourneyinnamibia
AT foerstermilena analysisofthebreastcancerjourneyinnamibia
AT schuzjoachim analysisofthebreastcancerjourneyinnamibia
AT dossantossilvaisabel analysisofthebreastcancerjourneyinnamibia
AT mccormackvalerie analysisofthebreastcancerjourneyinnamibia